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1528-4050 Copyright  2017 The Aa b b cThilo Jakob , Ulrich Mu¨ller , Arthur Helbling , and Edzard SpillnerPurpose of review
Component-resolved diagnostics makes use of defined allergen molecules to analyse IgE-mediated
sensitizations at a molecular level. Here, we review recent studies on the use of component-resolved
diagnostics in the field of Hymenoptera venom allergy (HVA) and discuss its benefits and limitations.
Recent findings
Component resolution in HVA has moved from single molecules to panels of allergens. Detection of specific
immunoglobulin E (sIgE) to marker and cross-reactive venom allergens has been reported to facilitate the
discrimination between primary sensitization and cross-reactivity and thus, to provide a better rationale for
prescribing venom immunotherapy (VIT), particularly in patients sensitized to both honeybee and vespid
venom. Characterization of IgE reactivity to a broad panel of venom allergens has allowed the identification
of different sensitization profiles that in honeybee venom allergy were associated with increased risks for side
effects or treatment failure of VIT. In contrast, component resolution so far has failed to provide reliable
markers for the discrimination of sensitizations to venoms of different members of Vespidae.
Summary
Component-resolved diagnostics allows a better understanding of the complexity of sensitization and
cross-reactivities in HVA. In addition, the enhanced resolution and precision may allow identification of
biomarkers, which can be used for risk stratification in VIT. Knowledge about the molecular composition of
different therapeutic preparations may enable the selection of appropriate preparations for VIT according
to individual sensitization profiles, an approach consistent with the goals of personalized medicine.
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The diagnosis of Hymenoptera venom allergy (HVA)
is based on the clinical history of a systemic/ana-
phylactic sting reaction and the detection of sensi-
tization to relevant insect venoms by skin testing
and/or detection of specific IgE antibodies in a
serum sample [1
&
]. In addition, cellular tests such
as the basophil activation test (BAT) can be used not
only in cases with a clear history but also with
negative or unclear results of skin or in-vitro IgE
tests. Depending on the geographical region, differ-
ent insect species are more or less likely to be
involved. The most frequent Hymenoptera sting
reactions in central and northern Europe are caused
by yellow jacket (Vespula spp.) and honeybee (Apis
mellifera), whereas in southern Europe and the
Americas, other wasps (e.g. Polistinae) are relevant.
In addition, systemic sting reactions can be caused
by ants, such as the jumper ant (Myrmecia) in
Australia, the Asian needle ant (Pachycondyla) in
Asia and the fire ant (Solenopsis) in the Americas.ht © 2017 Wolters Kluwe
uthor(s). Published by Wolters KluweHYMENOPTERA VENOM ALLERGENS
Whole venom preparations used for the detection
of IgE-mediated sensitization contain a plethora
of different components (such as proteins,r Health, Inc. All rights reserved.
r Health, Inc. www.co-allergy.com
KEY POINTS
 Currently, 75 venom allergens from 31 Hymenoptera
species have been identified and officially accepted as
allergens (www.allergen.org).
 Component resolution in routine diagnostics of HVA
allows improved discrimination between primary
sensitization and cross-reactivity, particularly in yellow
jacket and honeybee venom allergy.
 Component-resolved diagnostics provides additional
information on the complexity of the IgE and IgG4
immune response to Hymenoptera venom and allows
characterization of individual sensitization profiles.
 Molecular sensitization profiles can be used for risk
stratification that may lead to improved patient-related
outcomes in VIT.
Anaphylaxis and insect allergylipoproteins, glycoproteins, lipids etc.). The progress
of molecular biology over the last decades has
allowed a detailed characterization of relevant Hy-
menoptera venom allergens from different culprit
insects. The currently known Hymenoptera venom
allergens are summarized in Table 1. The list con-
tains 75 allergens from 31 species and for some of
these allergens, additional isoforms have been de-
scribed. In the last decades, mainly the prototypical
venom proteins (phospholipases, hyaluronidases
and antigen 5) of several species were identified
and accepted by the WHO/International Union of
Immunology Societies’ allergen nomenclature sub-
committee as novel allergens (www.allergen.org).
The latest additions to the official list of hyme-
nopteravenomallergensarePolyp2, ahyaluronidase
of Polybia paulista; Pol d 3, a dipeptidylpeptidase IV
(DPPIV) of Polistes dominula and Pac c 3, an antigen 5
from Pachycondyla chinensis, the Asian needle ant.
Poly p 2 from Polybia paulista, a clinically relevant
social wasp that frequently causes stinging accidents
in southeast Brazil, seems to have more pronounced
IgE reactivity than the yellow jacket hyaluronidases
Ves v 2 [3]. Pol d 3 from Polistes dominula is amember
of the cross-reactive DPPIV protein family found in
the majority of species and initially identified in
honeybee venom (HBV) and yellow jacket venom
(YJV). Pac c 3 was recently produced in recombinant
form and was shown to exhibit significant IgE reac-
tivity in patients with anaphylaxis [4
&
]. ImmunoCAP
inhibition studies further showed the high degree of
cross-reactivity to Ves v 5.
Additional potential allergens not yet included
in the official allergen list have recently been de-
scribed or in some cases evaluated as recombinant
proteins. Poly p 1, a phospholipase A1 from Polybia
paulista was cloned and produced in bacteria and Copyright © 2017 Wolters Kluwer 
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purposes [5
&
]. The main venom components of the
ectoparasitic ant-like bethylid wasp were recently
described [6]. Notably, the most abundant compo-
nents were acid phosphatase and antigen 5. Identify-
ing an acid phosphatase – amarker allergen found in
HBV – in wasp venom might open novel questions
about composition of venoms from even highly
diverse species.SPECIFIC IgE TO WHOLE VENOM
PREPARATIONS
Skin and/or sIgE tests with whole venom prepara-
tions are regarded as the gold standard in the diag-
nostics of HVA. Today, a number of companies offer
test systems for the detection of sIgE to insect ven-
oms. Results are usually expressed as kUA/l of aller-
gen-specific IgE based on calibration against a
heterologous IgE standard curve [7]. The interna-
tional cut-off for sIgE detection historically has been
set to 0.35 kUA/l. However, the lower limit of quan-
tification (LoQ), that is the analytical sensitivity, of
the most widely used modern autoanalyser-based
singleplex IgE assays has been accepted by the reg-
ulatory authorities as 0.1 kUA/l [8]. Thus, IgE anti-
body levels between 0.1 and 0.35 kUA/l should be
reported by the laboratory and must be interpreted
by the clinician within the context of the patient’s
history, clinical symptoms and total serum IgE
concentrations.
By using the cut-off value of 0.35kUA/l, positive
IgE test results to HBV have been reported in 90–
100% of patients with HVA [9,10
&
]. With the same
cut-off level, 83–97% of YJV-allergic patients have
been reported to test positive for IgE to YJV
[9,10
&
,11]. Interestingly, sIgE against Ves v 5 could
be detected in patients with a clear history of YJV
anaphylaxis who were negative for sIgE to YJV,
suggesting that the whole venom preparations had
a shortage of Ves v 5 immunoreactivity [12–15].
Spiking of YJV with recombinant Ves v 5 increased
sensitivity from 83 to 97% [11,15,16]. This improved
YJV reagenthas beenavailable for routinediagnostics
on the ImmunoCAP platform since 2012. In patients
with low total IgE and a clear history of anaphylaxis,
careful evaluation is needed as sIgE can sometimes
be hard to detect [17,18]. Here, IgE antibody levels
between 0.1 and 0.35kUA/l should be considered and
interpreted by the clinician as indicated above.MULTIPLE SENSITIZATIONS,
CROSS-REACTIVITY AND
COMPONENT-RESOLVED DIAGNOSTICS
Testing sIgE to whole venom preparations of differ-
ent Hymenoptera has one major limitation: In casesHealth, Inc. All rights reserved.
Volume 17  Number 5  October 2017
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Table 1. Current list of Hymenoptera venom allergens as of July 2017 (www.allergen.org)
Allergen Name/function
MW
(kDa) % DW
Potential
N-glycosylation
Diagnostic
availability
Honeybees (Apis mellifera, Apis cerana, Apis dorsata)
Api m 1, Api c 1, Api d 1 Phospholipase A2 17 12 1 þ (rApi m 1)
Api m 2 Hyaluronidase 45 2 3 þ (rApi m 2)
Api m 3 Saure phosphatase 49 1–2 2 þ (rApi m 3)
Api m 4 Melittin 3 50 – þ (rApi m 4)
Api m 5 Dipeptidylpeptidase IV 100 <1 6 þ (rApi m 5)
Api m 6 Protease inhibitor 8 1–2 – –
Api m 7 Protease 39 3 –
Api m 8 Carboxylesterase 70 4 –
Api m 9 Carboxypeptidase 60 4 –
Api m 10 CRP/Icarapin 55 <1 2 þ (rApi m 10)
Api m 11 MRJP 8,9 60,65 3,6 –
Api m 12 Vitellogenin 200 1 –
Bumble bees (Bombus terrestris, Bombus pennsylvanicus)
Bom t 1, Bom p 1 Phospholipase A2 16 1 –
Bom t 4, Bom p 4 Protease 27 – –
Yellow Jackets (Vespula vulgaris, Vespula flavopilosa, Vespula germanica, Vespula maculifrons, Vespula pensylvanica, Vespula
squamosa, Vespula vidua)
Ves v 1, Ves m 1, Ves s 1 Phospholipase A1 34 6–14 – þ (rVes v 1)
Ves v 2, Ves m 2 Hyaluronidase 45 1–3 2 –
Ves v 3 Dipeptidylpeptidase IV 100 6 –
Ves v 5, Ves f 5, Ves g 5, Ves m 5, Ves p 5,
Ves s 5, Ves vi 5
Antigen 5 23 5–10 – þ (rVes v 5)
Ves v 6 Vitellogenin 200 4 –
Hornets (Vespa crabro, Vespa magnifica, Vespa mandarina)
Vesp c 1, Vesp ma 1, Vesp m 1 Phospholipase A1 34 – –
Vesp ma 2 Hyaluronidase 35 –
Vesp c 5, Vesp ma 5, Vesp m 5 Antigen 5 23 1 –
Bald-faced hornet (e.g. Dolichovespula maculata, Dolichovespula arenaria)
Dol m 1 Phospholipase A1 34 2 –
Dol m 2 Hyaluronidase 42 2 –
Dol m 5, Dol a 5 Antigen 5 23 – –
European paper wasps (Polistes dominula, Pol istes gallicus)
Pol d 1, Pol g 1 Phospholipase A1 34 1 þ (rPol d 1)
Pol d 3 Dipeptidylpeptidase IV 100 4 –
Pol d 4 Protease 33 6 –
Pol d 5, Pol g 5 Antigen 5 23 – þ (rPol d 5)
American paper wasps (Polistes annularis, Polistes exclamans, Polistes fuscatus, Polistes metricus)
Pol a 1, Pol e 1 Phospholipase A1 34 – –
Pol a 2 Hyaluronidase 38 2 –
Pol e 4 Protease ? –
Pol a 5, Pol e 5, Pol f 5, Pol m 5 Antigen 5 23 – –
South American paper wasps (Polybia paulista, Polybia scutellaris)
Poly p 1 Phospholipase A1 34 – –
Poly p 2 Hyaluronidase 33 2 –
Poly p 5, Poly s 5 Antigen 5 21 – –
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Table 1 (Continued )
Allergen Name/function
MW
(kDa) % DW
Potential
N-glycosylation
Diagnostic
availability
Ants
Fire ants (Solenopsis invicta, Solenopsis richteri, Solenopsis saevissima)
Sol i 1 Phospholipase A1 18 3 –
Sol i 2, Sol r 2, Sol s 2 14 – –
Sol i 3, Sol r 3, Sol s 3 Antigen 5 24–26 2 –
Sol i 4 12 – –
Jumper ant (Myrmecia pilosula)
Myr p 1 7.5, 5.5 – –
Myr p 2 Pilosulin-3 8.5, 2.4 – –
Myr p 3 Pilosulin-4.1 – –
Asian needle ant (Pachycondyla chinensis)
Pac c 3 Antigen 5 23 – –
Modified with permission from [2].
Of note, the Vespula vulgaris antigen Ves v 4, a protease, has been cloned and recombinantly expressed, but has so far not officially been confirmed as an allergen.
Anaphylaxis and insect allergyof double- or triple-positive test results against
different venoms, the assays do not allow discrimi-
nation between cross-reactivity and primary sensi-
tization to multiple venoms. According to the
assessment of the current American Stinging Insect
Hypersensitivity Practice Parameter [19
&
], immuno-
logical cross-reactivity is extensive between hornet
and YJV, somewhat less extensive between yellow
jacket and hornet with wasp venoms and less com-
mon between honeybee and Vespidea venoms. Data
from European studies, however, suggest that there
is quite a substantial cross-reactivity also between
honeybee and yellow jacket venom [10
&
,20–22]. In
our own patient cohort (n¼815) from the south/
west region of Germany, 45% of patients with ana-
phylactic sting reactions display positive sIgE to
both HBV and YJV [1
&
,20].
Double positivity may either reflect true double
sensitization to both venoms or may be caused by
IgE antibodies to cross-reactive carbohydrate deter-
minants (CCD), which are present in themajority of
hymenoptera venom allergens [21,23,24] or to ho-
mologous peptide sequences in proteins present in
both venoms.
Analysis of single allergens in HBV and YJV
allowed the identification of allergens that are present
only in one or the other venom and may therefore,
serve as so-called marker allergens to unequivocally
identify a primary sensitization to a given venom. In
the discrimination between primary HBV and YJV
sensitization, Ves v 1 and Ves v 5 serve as marker
allergens for YJV sensitization whereas Api m 1, Api
m 3, Api m 4 and Api m 10 for HBV sensitization.
Other allergens are likely to be cross-reactive
based on sequence homology, such as the Copyright © 2017 Wolters Kluwer 
366 www.co-allergy.comhyaluronidases Api m 2 and Ves v 2, the dipeptidyl-
peptidases Api m 5 and Ves v 3 and the vitellogenins
Apim12andVes v 6 [25–28]. Significantly, the cross-
reactivity of the hyaluronidases appears to be mostly
based on IgE reactivity to CCD epitopes as demon-
strated with YJV hyaluronidases (Ves v 2a, Ves v 2b)
with and without CCDs [28]. In contrast, IgE
reactivity to CCD-free HBV hyaluronidase Api m 2
is quite prevalent in HBV-allergic patients ranging
from 43 to 52% [29,30
&&
,31
&&
]. Structural data dem-
onstrate that, despitehigh sequence identity, Apim2
and Ves v 2 display very little homology when it
comes to allergen surface epitopes [32]. Thus, IgE
reactivity to CCD-free Api m 2 may also with a grain
of salt be interpreted as indicator for a primary
HBV sensitization.RECOMBINANT VENOM ALLERGENS FOR
ROUTINE DIAGNOSTICS OF
HYMENOPTERA VENOM ALLERGY
Recently, recombinant venom allergens that are
devoid of CCD reactivity have been introduced
for routine sIgE diagnostics to improve the discrimi-
nation between primary sensitization and cross-re-
activity [10
&
,13,22]. The first study on the use of
rApi m 1 and rVes v 5 in IgE diagnostics reported a
frequency of sensitization of 97% to Api m 1 among
HBV and 87% to Ves v 5 among YJV sensitized
patients, using a then available liquid-phase detec-
tion system [10
&
]. Subsequent studies, using the
currently available test systems andmarker allergens
for YJV, reported sensitization frequencies for rVes v
5 as 84.5–90% and for rVes v 1 as 33–54%. The
combination of sIgE measurements in rVes v 5 andHealth, Inc. All rights reserved.
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allergic patients [11,15,20,33,34]. Additional meas-
urements of sIgE to Ves v 2 and Ves v 3 were
suggested to further increase the ability to detect
YJV sensitization [12], which, however, could not be
confirmed by a follow-up study [35].
In contrast to the initial report [10
&
], the fre-
quency of sensitization to rApi m 1 in HBV-allergic
patients was found to be lower in subsequent studies
that used currently available test systems. Reported
frequencies range from 58 to 80% [13,31
&&
,36,37],
leaving a considerable gap in the ability to detect
HBV sensitization by using component-based diag-
nostic tools. Thus, lack of sensitization to Api m 1 in
patients suspected of having HBV allergy has been
regarded as insufficient to rule out primary HBV
sensitization.
The difference in Api m 1 sensitization rates
(ranging from 58 to 80%) has been suggested to
reflect regional differences [14] or differences in
the definition of the patient population [13]. In
addition, the sensitivity of Api m 1 may partly
depend on the test system used. Recently, direct
comparison of sIgE levels with Api m 1 measured
on the Immulite fluid phase test system and the
ImmunoCAP solid phase test system suggested
a higher sensitivity for the Immulite system
[38
&
,39
&
]. It was speculated that IgE binding
capacity of the recombinant Api m 1 used in the
ImmunoCAP systemmay be diminished because of
altered protein folding [38
&
,39
&
]. However, this
notion was contradicted by a direct comparison
of IgE binding with purified natural Api m 1, which
was found to be identical in CCD-negative sera
[40]. A more likely cause is an apparent difference
in the heterologous calibration system between
the two assays, as suggested by one study [39
&
].
Indeed, two comparative studies using chimeric
IgE antibodies to different allergens provided
convincing evidence that the Immulite system
tends to overestimate the actual levels of sIgE to
a given allergen as approximately three to five-
fold [41,42], hence explaining the higher fre-
quency of test results exceeding the cut-off level
chosen.
Aside from Api m 1, additional major allergens
have been reported in HBV allergy. Analysis of sIgE
reactivity to a panel of HBV allergens (Api m 1–5,
Api m 10) allowed the detection of 94% of patients
with HBV allergy and demonstrated that patients
with HBV allergy display a broad spectrum of sensi-
tization profiles [31
&&
]. Particularly interesting was
the finding that HBV-specific marker allergens rApi
m 3 and rApi m 10 allowed the detection of primary
HBV sensitizations in about two thirds of Api m
1 negative sera [43], demonstrating that these Copyright © 2017 Wolters Kluwe
1528-4050 Copyright  2017 The Author(s). Published by Wolters Kluwecomponents help to reduce the diagnostic gap in
detecting HBV sensitization.
HBV allergens currently available for routine sIgE
diagnostics include rApi m 1, rApi m 2, rApi m 3, Api
m 4, rApi m 5 and rApi m 10 (Table 2). By using this
panel of allergens, a recent study [29] reported a
combined sensitization frequency of only 79%
among the HBV-allergic patients studied and con-
cluded that the currently available allergens are still
not sufficient to reliably identify HBV sensitization.
The lower frequency of sensitization to at least one of
the HBV components observed in this study, as com-
pared with the study by Kohler et al. [31
&&
] may have
been due to differences in the patient populations, in
particular the number of HBV monosensitized and
HBV and YJV double-sensitized patients. We previ-
ously demonstrated that in patients with HBV aller-
gy, concomitant sensitization to YJV was associated
with higher levels of both total andHBV-specific IgE,
as well as higher levels of sIgE to all HBV allergens
tested [31
&&
], suggesting effects that were indepen-
dent of serological cross-reactivity. Accordingly,HBV
monosensitized patients mostly displayed lower sIgE
levels and recognition of fewer allergens, whereas
double-sensitized patients often recognizedmultiple
HBV allergens and with higher sIgE levels [31
&&
]. The
same trend was observed in a separate population of
patients with YJV allergy, suggesting that this might
reflect a more advanced state of atopic immune
deviation in the double-sensitized population [31
&&
].
Even more difficult than resolution between
HBV and YJV sensitization is the discrimination
between sensitization to yellow jacket and Polistes
venoms, which is of particular relevance in Mediter-
ranean countries and the Americas. Due to a high
degree of IgE cross-reactivity, unequivocal discrimi-
nation is rarely achieved. Significantly, Polistes ven-
om proteins are devoid of CCD reactivity [44], so
that cross-reactivity is mostly caused by homolo-
gous proteins as described for the hyaluronidases
(Ves v 2 and the homologous protein in Polistes
venom), for the dipeptidylpeptidases (Ves v 3, Pol
d 3), the group 5 antigens (Ves v 5, Pol d 5) and to a
lesser extent for group 1 antigens (Ves v 1, Pol d 1).
Among these venoms, which is the most likely
primary sensitizer may however be indicated by
the relative level of sensitization to them. To this
end, the combination of group 1 and group 5 aller-
gens were reported to identify the most probable
sensitizing insect in two thirds of the patients stud-
ied, whereas the hyaluronidases (Ves v 2 and the
homologous protein in Polistes venom) did not pro-
vide any additional value [45]. Currently available
allergens for routine sIgE diagnostics to yellow jack-
et and Polistes venom include rVes v 1, rVes v 5, rPol
d 1 and rPol d 5 (Table 2).r Health, Inc. All rights reserved.
r Health, Inc. www.co-allergy.com 367
Table 2. Selected test systems for sIgE detection to Hymenoptera venom allergens as of July 2017
Allergen Manufacturer Test system Significance
Honeybee
Api m 1 Thermo Fisher
Siemens
Euroimmun
Dr Fooke Laboratories
Macro Array Diagnostics
(ALEX and Faber test)
Singleplex, multiplex
Singleplex
Multiplex
Singleplex
Multiplex
Marker allergen for HBV sensitization, allows discrimination
between HB and YJ/Polistes venom sensitization
Api m 2 Thermo Fisher
Siemens
Euroimmun
Dr Fooke Laboratories
Macro Array Diagnostics (ALEX)
Singleplex
Singleplex
Multiplex
Singleplex
Multiplex
Major HBV allergen. Due to limited cross-reactivity with
hyaluronidases of YJV or Polistes venom in the absence of
CCDs, IgE to Api m 2 can be used as indicator for HBV
sensitization
Api m 3 Thermo Fisher Singleplex Marker allergen for HBV sensitization, allows discrimination
between HB and YJ/Polistes venom sensitization
Api m 4 Macro Array Diagnostics (Faber test) Multiplex Marker allergen for HBV sensitization, allows discrimination
between HB and YJ/Polistes venom sensitization
Api m 5 Thermo Fisher Singleplex Major HBV allergen. High cross-reactivity with
dipeptidylpeptidase of YJV and Polistes venom prevents its
use as marker allergen
Api m 10 Thermo Fisher
Euroimmun
Dr Fooke Laboratories
Macro Array Diagnostics (ALEX)
Singleplex
Multiplex
Singleplex
Multiplex
Marker allergen for HBV sensitization, allows discrimination
between HB and YJ/Polistes venom sensitization
Yellow jacket
Ves v 1 Thermo Fisher
Euroimmun
Singleplex
Multiplex
Marker allergen for YJV sensitization, allows discrimination
between YJV and HBV sensitization; n.b. cross-reactivity
with phospholipase of Polistes venom
Ves v 5 Thermo Fisher
Siemens
Euroimmun
Dr Fooke Laboratories
Macro Array Diagnostics (ALEX)
Singleplex, multiplex
Singleplex
Multiplex
Singleplex
Multiplex
Marker allergen for YJV sensitization, allows discrimination
between YJV and HBV sensitization; n.b. high cross-
reactivity with antigen 5 of Polistes venom
European paper wasp
Pol d 1 Euroimmun Multiplex Marker allergen for Polistes venom sensitization, allows
discrimination between Polistes and HBV sensitization; n.b.
cross-reactivity with phospholipase of YJV
Pol d 5 Thermo Fisher
Euroimmun
Macro Array Diagnostics (ALEX)
Singleplex
Multiplex
Multiplex
Marker allergen for Polistes venom sensitization, allows
discrimination between Polistes and HBV sensitization; n.b,
high cross-reactivity with phospholipase of YJV
CCD, cross-reactive carbohydrate determinant; HBV, honeybee venom; YJV, yellow jacket venom.
Anaphylaxis and insect allergyAdditional members of the Vespidae family play
a prominent role in other areas of the world, such as
the genus Polybia in South America. Polybia belong
to the subfamily of Polistinae and a number of aller-
gens have recently been cloned and characterized.
These Polybia allergens display a high degree of
sequence homology to their counterparts in yellow
jacket and Polistes venoms. Again, no uniquemarker
allergen has been identified, which would likely
allow reliable discrimination between Polistinae
and Vespinae venom sensitization.
Finally, cross-reactivity is also observed between
ant venom and YJV. In particular, the antigen 5
allergens exhibit significant degree of sequence Copyright © 2017 Wolters Kluwer 
368 www.co-allergy.comidentity, rendering differentiation of sensitization
to venom of Formicoidea and Vespoidea superfamily
members difficult.
In conclusion, the currently available recombi-
nant Hymenoptera venom allergens are useful for
the identification of sensitizations to YJV and HBV
allergens, not confounded byCCD reactivity, even if
a minority (5–20%) of HBV-allergic patients is not
sensitized to any of the available HBV allergens.
Although Ves v 1 and Ves v 5 negative results
exclude YJV sensitization with a high likelihood,
negative results to the HBV-specific allergens Api
m 1, Api m 2, Api m 3, Api m 4 and Api m 10 do
not necessarily exclude HBV sensitization. Here,Health, Inc. All rights reserved.
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sIgE HBV (i1)
sIgE YJV (i3) tryptase&Step I 
sIgE: Api m 1, Api m 2, Api m 3, Api m 4, Api m 10 
sIgE: Ves v 1, Ves v 5
Step II 
HBV      +
YJV       +
HBV    +
YJV     –
HBV sensitization
Api m 1, 2, 3, 4, 10 +
Ves v 1, 5  –
YJV sensitizationHBV + YJVdouble
sensitization
HBV       –
YJV       +
Api m 1, 2, 3, 4, 10 +
Ves v 1, 5  +
Api m 1, 2, 3, 4, 10 –
Ves v 1, 5  +
FIGURE 1. Two-step diagnostic algorithm for an improved discrimination between yellow jacket venom and honeybee venom
sensitization. Step I: Baseline in-vitro diagnostics; Step II: Component-resolved diagnostics in cases of honeybee venom and
yellow jacket venom double-positive cases, or in cases of discrepancies between history, skin test and serology. Please refer to
Table 2 for availability of single allergens for routine diagnostics by different manufacturers. HBV, honeybee venom; YJV,
yellow jacket venom. Modified with permission from [2].
Component resolved diagnostics for hymenoptera venom allergy Jakob et al.consideration of low (0.1–0.35 kUA/l) IgE levels to
HBV marker allergens, comparison of IgE levels
with cross-reactive allergens or the identification
of additional HBVmarker allergens would be helpful
towards optimizing the diagnostic precision. No
major marker allergens that would support defini-
tive discrimination of sensitizations to venoms
of different Vespidae subfamilies have so far been
identified.
Based on the available allergens, a diagnostic
algorithm has been suggested for an improved
discrimination between YJV and HBV sensitization
(Fig. 1, modified from [2]).COMPONENT-RESOLVED DIAGNOSTICS
FOR PERSONALIZED RISK
STRATIFICATION IN VENOM
IMMUNOTHERAPY
Component-resolved diagnostics not only supports
improved diagnostic precision in HVA but also ena-
bles detailed characterizationof sensitizationprofiles
of individual patients. Particularly in HBV allergy,
patients display a wide spectrum of sensitization Copyright © 2017 Wolters Kluwe
1528-4050 Copyright  2017 The Author(s). Published by Wolters Kluweprofiles [31
&&
], whichmight be associated with differ-
ent risks in venom immunotherapy (VIT).
In this context, it was of interest that some of the
newly identified major allergens in HBV, namely
Api m 3 and Api m 10, were reported to be under-
represented or absent in a number of therapeutic
preparations [46
&&
]. This observation prompted us to
ask whether treatment failure in honeybee VIT may
be associated with certain sensitization profiles.
In a retrospective study of VIT-treated HBV-allergic
patients, comparison of sIgE levels with HBV and
individual allergens identified predominant sensiti-
zation to Api m 10 (>50% of sIgE to HBV) as the best
predictor of treatment failure with an odds ratio
8.44. No such signal was obtained for dominant
sensitization to any of the other allergens [30
&&
].
In this study, again some of the therapeutic HBV
preparations analysed displayed lack of Api m 10,
whereas their Api m 1 content was comparable with
that of crude HBV [30
&&
]. A follow-up analysis of the
allergen composition of four different therapeutic
venom preparations confirmed the previously
reported lack or underrepresentation of Api m 10
[47
&
]. In addition, shortage of Api m 3 and Api m 5r Health, Inc. All rights reserved.
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Anaphylaxis and insect allergywas observed in some preparations. Of note, al-
though some allergens are present in large quanti-
ties (Apim 1, Apim 2 and Apim 4with 10%, 3% and
>40% of venom dry weight, respectively), Api m 3,
Api m 5 and Api m 10 belong to the low abundance
allergenswith less than 1%of the venomdryweight.
Currently, we do not fully understand the role of Api
m 10 in HBV allergy and tolerance induction during
VIT. However, the high prevalence of Api m 10
sensitization (>50%), the shortage of Api m 10 in
widely used therapeutic HBV preparations and the
significant association of dominant Api 10 sensiti-
zation and treatment failure strongly suggest that
Api m 10 is a relevant allergen and that this kind of
component-resolved diagnostics may be useful for
the risk stratification in honeybee VIT. Even though
prospective studies are still lacking, the clinical im-
plication would be that HBV-allergic patients with
dominant sensitization to Api m 10 are at increased
risk for treatment failure in honeybee VIT and
should preferably be treated with HBV preparations
demonstrated to contain an adequate amount of Api
m 10, sufficient to induce a robust IgG4 response in
treated patients.
In a recent study, component-resolved diagnos-
tics using nApi m 1, rApi m 2 and Api m 4 demon-
strated a high prevalence of Api m 4 sensitization
among HBV-allergic patients who experienced sys-
temic reactions during the induction of honeybee
VIT [48]. A subsequent prospective study stratified
HBV-allergic patients according to their sIgE to Api
m 4 into two groups (<0.98 or >0.98KUA/l) and
confirmed higher rates of systemic reactions during
the VIT induction phase in the latter group. In
addition, this group was characterized by increased
baseline skin reactivity, increased base line HBV sIgE
andmore persistent responses in intradermal testing
during VIT [49
&&
].
This data supports the concept that component-
resolved diagnostics will enable us to define differ-
ent endotypes of HBV allergy and based on the
individual’s sensitization profile, allow a personal-
ized risk stratification as well as an optimization of
treatment protocols.UNRESOLVED/OPEN ISSUES
For the use in clinical routine, test reagents ideally
should allow a definite discrimination between sen-
sitization to one or the other Hymenoptera venom.
Marker allergens such as Ves v 5, Ves v 1 and Apim 1,
Api m 3, Api m 4 and Api m 10 allow such discrimi-
nation between YJV and HBV sensitization in the
majority of cases. However, the limited sensitization
prevalence to HBV marker allergens only allows
detection of 80–90% of HBV-allergic patients Copyright © 2017 Wolters Kluwer 
370 www.co-allergy.com[29,30
&&
,31
&&
]. To further reduce this diagnostic
gap, it should be helpful to take advantage of the
low end of the assays’ measuring range and consider
IgE levels down to the LoQ of 0.1 kUA/l, particularly
in patients with low total IgE. In addition, direct
quantitative comparison of IgE levels with corre-
sponding cross-reactive HBV and YJV allergens such
as Api m 2 and Ves v 2, Api m 5 and Ves v3 or Api 12
and Ves v 6 might prove useful towards identifying
the primary sensitizer. The best example are the
hyaluronidases Api m 2 and Ves v 2. Api m 2 is a
major allergen in HBV allergy, in contrast, IgE reac-
tivity to Ves v 2 is mostly CCD-related and only few
patients with YJV allergy display CCD-independent
reactivity to Ves v 2 [27,28]. The same approach
could be useful in the discrimination between sen-
sitizations to Vespid and Polistinae venoms [45].
However, so far no manufacturer offers test reagents
that allow this kind of direct comparison of IgE
reactivity with cross-reactive Hymenoptera venom
allergens.
The BAT by usingwhole venompreparations has
been demonstrated to be helpful in the investiga-
tion of double-sensitized patients or in patients with
a clear history of sting reactions but negative sIgE
and skin tests [17,50]. The BAT may be of similar
diagnostic advantage by using single CCD-free aller-
gens, as recently demonstrated in YJV-allergic
patients [12]. So far, component resolution in BAT
has only been performed in academic research set-
tings. For routine testing, however, a stringent stan-
dardization of allergen preparations, stability and
test procedures would be required. Provided this can
be achieved, BAT may be helpful to close diagnostic
gaps that sIgE determinations leave open.
Finally, data obtained so far on the potential
of component-resolved diagnostics for improved
risk stratification in VIT is still limited. Prospective
randomized studies are needed to put current
hypotheses to the test. This is especially true for
the retrospective data on Apim 10 regarding the VIT
response in patients with HBV allergy.CONCLUSION
Component resolution provides for a better under-
standing of the complexity of sensitization and
cross-reactivities in HVA. In addition, it has opened
up new avenues for identification of biomarkers that
may allow risk stratification for VIT responses. The
continuously expanding field of venom allergens
will permit enhanced resolution and precision in
the diagnostic testing of patients with suspected
HVA. In addition, improvedmethods of monitoring
therapeutic outcomes and detailed knowledge
about the molecular composition of differentHealth, Inc. All rights reserved.
Volume 17  Number 5  October 2017
Component resolved diagnostics for hymenoptera venom allergy Jakob et al.therapeutic preparations will enable the selection of
appropriate venom preparations for VIT according
to the individual sensitization profile. This will help
move VIT from a generalized towards a precision-
targeted immunotherapy approach, consistent with
all other efforts to achieve the goals of personalized
medicine.
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